[Termination of pregnancy and evacuation of the uterine contents in the second trimester. Use of a prostaglandin E2 analog: sulprostone].
The authors used sulprostone on 165 women whose pregnancies had lasted more than 12 weeks. The principal indications were: intra-uterine fetal deaths in 65 cases and an antenatal diagnosis of fetal malformations in 75 cases. Three routes of administration of the drug were employed: extra-amniotic in 15 women; intravenous in 62 women; intramuscular in 88 women. The doses used (adding together the intramuscular and intravenous routes) were: ampoule of 500 micrograms of sulprostone in 25% of cases; ampoules in 50% of cases; ampoules in 25% of cases. It was found to be very effective: by the intravenous route 88.70% expelled the fetus in 24 hours with a mean induction delivery time of 11 hours; by the intramuscular route 89.77% expelled in 24 hours with a mean induction delivery time of 11 hours 45 minutes. The side effects were not common: nausea in 17.6%; vomiting in 16.4% and diarrhoea in 6%. Ther marked effectiveness of sulprostone on the one hand and the good tolerance on the other indicate the effects of this product, which are a strong action on the uterus and a feeble action on the smooth muscle of other organs.
D000019:Abortifacient Agents / Q000008:administration & dosage; D000028:Abortion, Induced; D000328:Adult; D000650:Amnion; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007267:Injections; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008875:Middle Aged; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000009:adverse effects
D000019:Abortifacient Agents; D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone
Interrompre la grossesse et évacuer le contenu utérin au cours du deuxième trimestre. Utilisation d'un analogue de prostaglandines E2: le sulprostone.